New drugs from marine organisms in Alzheimer's disease

Patrizia Russo, Aliaksei Kisialiou, Palma Lamonaca, Rossana Moroni, Giulia Prinzi, Massimo Fini

Research output: Contribution to journalArticlepeer-review

Abstract

Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder. Current approved drugs may only ameliorate symptoms in a restricted number of patients and for a restricted period of time. Currently, there is a translational research challenge into identifying the new effective drugs and their respective new therapeutic targets in AD and other neurodegenerative disorders. In this review, selected examples of marine-derived compounds in neurodegeneration, specifically in AD field are reported. The emphasis has been done on compounds and their possible relevant biological activities. The proposed drug development paradigm and current hypotheses should be accurately investigated in the future of AD therapy directions although taking into account successful examples of such approach represented by Cytarabine, Trabectedin, Eribulin and Ziconotide. We review a complexity of the translational research for such a development of new therapies for AD. Bryostatin is a prominent candidate for the therapy of AD and other types of dementia in humans.

Original languageEnglish
Article number5
JournalMarine Drugs
Volume14
Issue number1
DOIs
Publication statusPublished - Jan 1 2016

Keywords

  • Alzheimer's disease
  • Bryostatin
  • Clinical/preclinical studies
  • Marine drugs
  • Mechanisms of activity
  • New drugs

ASJC Scopus subject areas

  • Drug Discovery

Fingerprint Dive into the research topics of 'New drugs from marine organisms in Alzheimer's disease'. Together they form a unique fingerprint.

Cite this